Value of innovation in hematologic malignancies: A systematic review of published cost-effectiveness analyses

Blood

Volumn 125, Issue 12, 2015, Pages 1866-1869

  Saret, Cayla J ^a   Winn, Aaron N ^b   Shah, Gunjan ^a   Parsons, Susan K ^a   Lin, Pei Jung ^a   Cohen, Joshua T ^a   Neumann, Peter J ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BORTEZOMIB; DASATINIB; IMATINIB; LENALIDOMIDE; RITUXIMAB; ANTINEOPLASTIC AGENT;

BLOOD; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHATIC LEUKEMIA; MEDLINE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMIC MODEL; ECONOMICS; HEALTH ECONOMICS; HEMATOLOGIC NEOPLASMS; MASS COMMUNICATION; QUALITY OF LIFE; REGISTER; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DECISION MAKING; DIFFUSION OF INNOVATION; ECONOMICS, MEDICAL; HEMATOLOGIC NEOPLASMS; HUMANS; MODELS, ECONOMIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES; TREATMENT OUTCOME;

EID: 84925355049     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-592832     Document Type: Review

References (17)

1. Haznedaroʇlu IC. Current management of chronic myeloid leukemia with tyrosine kinase inhibitors. Turk J Haematol. 2013;30(3):247-255.
2. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439-4442.
3. Bianchi G, Ghobrial IM. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leuk Lymphoma. 2013;54(2):229-241.
4. Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102(2):82-88.
5. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the costutility literature, 1976-2001. Value Health. 2005;8(1):3-9.
6. Siegel JE, Weinstein MC, Russell LB, Gold MR; Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. JAMA. 1996;276(16):1339-1341.
7. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253-1258.
8. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797.
9. Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. Eur J Haematol. 2010;85(6):484-491.
10. Doss S, Hay N, Sutcliffe F. NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma. Lancet Oncol. 2011;12(9):837-838.
11. Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol. 1997;15(7):2673-2682.
12. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332(7543):699-703.
13. Mason AR, Drummond MF. Public funding of new cancer drugs: Is NICE getting nastier? Eur J Cancer. 2009;45(7):1188-1192.
14. National Institute for Health and Clinical Excellence (NICE). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia. NICE technology appraisal guidance TA251. April 2012. Available at: http://www.nice.org.uk/guidance/ta251.
15. Husereau D, Drummond M, Petrou S, et al; ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231-250.
16. rd ed. Oxford: Oxford University Press; 2005:7-26.
17. Gold MR, Russell LB, Siegel JE, Weinsten MC. Cost-effectiveness analysis as a guide to resource allocation in health: roles and limitations. In: Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:3-24.